Navigation Links
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Date:9/12/2008

- Upfront, milestone payments and promotional investment totaling up to

$385 million plus royalties -

PALO ALTO, Calif., Sept. 12 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it has entered into an agreement granting exclusive rights to Ranexa(R) (ranolazine prolonged release tablets) in Europe and other countries to the Menarini Group. Menarini, with its significant pan-European presence, makes the most physician calls for cardiovascular products and has the fourth largest pharmaceutical sales team for delivering medical information to physicians in Europe.

In total, the agreement grants rights to Menarini for Ranexa in 68 countries, including the 27 countries of the European Union (EU), the Commonwealth of Independent States, and select countries of Central and South America.

In the agreement, Menarini has committed to make an upfront payment of $70 million in consideration of the rights granted and in recognition of the R&D investments made by CV Therapeutics. In addition, Menarini will potentially make additional payments and investments totaling up to $315 million (based on the current currency exchange rate) for commercial and development milestones and promotional and detailing commitments. The commercial milestones are primarily linked to sales levels and the development milestones are linked to approval of Ranexa in Europe for certain additional indications that are jointly developed. The agreement provides mechanisms for the parties to collaborate and share the costs of joint development of Ranexa.

Menarini will be responsible for commercial activities and pursuing regulatory and pricing approvals. As part of the agreement, Menarini has com
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics to Host Investor Day in Milan, Italy on Friday, October 3, 2008
2. Halozyme Therapeutics to Present at Upcoming Investor Conferences
3. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
4. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
7. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
11. Cell Therapeutics, Inc. Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... (PRWEB) July 29, 2014 EXpressLO LLC, ... lift out specimen preparation solutions, has been granted patent ... for specimen manipulation methods incorporating a unique specimen carrier ... This is the second company patent for EXpressLO LLC ... , These complementary patents extend EXpressLO’s portfolio ...
(Date:7/28/2014)... July 28, 2014 The Workgroup for ... on the use of health IT to create efficiencies ... Plan Identifier (HPID) Workgroup has developed an issue ... Plan and Payer?” The HPID Workgroup, a part of ... the Centers for Medicare and Medicaid Services (CMS) to ...
(Date:7/28/2014)... , July 28, 2014 Research ... "Global Synthetic Biology Market 2014-2018" report to ... The term synthetic biology covers the designing ... organisms as well as the redesigning of natural biological ... considered to be a form of extreme genetic engineering ...
(Date:7/28/2014)... Boston, MA (PRWEB) July 28, 2014 ... with two researchers to further develop potential treatments for ... brain tumor, in combination with their patented vaccine platform, ... and Duke University, are based on the work of ... of Neurosurgery at The Preston Robert Tisch Brain Tumor ...
Breaking Biology Technology:EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4
... one of six states to receive a $50,000 grant ... network further into the Internet age. , ,Wisconsin's grant ... of Justice Assistance, which houses the Wisconsin Justice ... maintaining, promoting and coordinating automated justice information systems. , ...
... the learning acquired in the program but rather the blue-chip roster ... mythology goes, you can call on a fellow alum to help ... will be of value once again. , ,Though I can't say ... can attest to the power of alumni connections. , ,While I'm ...
... of health-care and business technology, announced a seven-year contract with ... Information System (MMIS). The new system is expected to be ... contracts EDS to implement its InterChange health system on the ... Services . The contract is worth approximately $189 million and ...
Cached Biology Technology:State receives grant for justice information sharing 2Pay attention to your alumni connections when job hunting 2Pay attention to your alumni connections when job hunting 3Pay attention to your alumni connections when job hunting 4State picks long-time vendor for $189m Medicaid information system 2
(Date:7/28/2014)... the bug hunter, but the target of his work ... identified with special methods and instruments. Benjamin Hause, an ... Laboratory at Kansas State University, recently published an article ... is an important find in the United States. , ... know what it was," Hause said. "We used next-generation ...
(Date:7/28/2014)... that can help advance the genetic engineering of ... has been developed by researchers with the U.S. ... a multi-institutional partnership led by Lawrence Berkeley National ... an assay that enables scientists to identify and ... components in the biosynthesis of plant cell walls. ...
(Date:7/28/2014)... for Biologically Inspired Engineering at Harvard University today ... commercialized by a newly formed private company to ... medicine products. The announcement follows a ... Development (OTD) and the start-up Emulate Inc., relating ... Organs-on-Chips platform. , "This is a big ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3How sweet it is 2How sweet it is 3Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3
... pays to be rare—think of a one-of-a-kind diamond, a ... , Now, new research suggests that being rare has ... University of Toronto Mississauga who in the 1980s discovered ... fruit flies, has identified the benefit of rarity in ...
... the La Jolla Institute for Allergy & Immunology have ... be reduced ?and in some cases eliminated ?through the ... the immune system. The research team’s findings, based ... implications for other chronic virus infections, such as hepatitis ...
... how ocean circulation is working in the current that ... from underwater volcanoes. The details are published in Nature ... Garabato of the National Oceanography Centre, Southampton (formerly based ... 'short-circuit' in the circulation of the world's oceans that ...
Cached Biology News:Survival of the rarest: Fruit flies shed light on the evolution of behavior 2LIAI scientists make important finding on cytomegalovirus transmission 2'Short-circuit' found in ocean circulation 2
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
... applications for the use of small interfering ... via the RNA interference (RNAi) pathway have ... molecular biology fields. siRNA for experimental use ... or enzymatically, and then transfected into the ...
... unique collision reaction interface (CRI) system*, ... troublesome spectroscopic interferences. The result is ... the worry of complex multipole or ... And, by coupling autotuning of all ...
Acetylcholinesterase (human brain, AChE)...
Biology Products: